Berkshire Hathaway Inc. (BRK-B) vs Merck & Co., Inc. (MRK)
See how Berkshire Hathaway Inc. and Merck & Co., Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$526.47
NYSE
$147.47
NYSE
Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.
View Full PageKey Metrics Comparison
Berkshire Hathaway Inc.BRK-B
Market Cap$1.127T
Price$526.47
24h Change+1.13%
24h Volume$2.73M
Employees387,800
Shares OutstandingN/A
Merck & Co., Inc.MRK
Market Cap$363.821B
Price$147.47
24h Change+3.86%
24h Volume$5.6M
Employees73,000
Shares Outstanding2,469,879,206
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
BRK-B
75.6%MRK
24.4%Volume Share
Share of combined 24h volume
BRK-B
32.8%MRK
67.2%24h Performance
Price change over last 24 hours
BRK-B
1.13%MRK
3.86%Price Comparison
Berkshire Hathaway Inc.
Merck & Co., Inc.